Armistice Capital’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Armistice Capital’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,335	Closed	-$1.02M	–	202
2021 Q4	$1.02M	Buy	+3,335	New	+$2.09M	0.02%	128
2021 Q1	–	Sell	-2,505	Closed	-$3.54M	–	147
2020 Q4	$3.54M	Buy	+2,505	New	+$5.12M	0.12%	89

Other funds holding BXRX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Armistice Capital's BXRX Position: Q1 2022 in Review

Armistice Capital sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2022, closing a stake of 3,335 shares — an estimated $1.02M sold.

Armistice Capital first reported a position in BXRX in Q4 2020 and held it in 2 quarters. The position peaked at $3.54M in Q4 2020. 19 funds tracked by Wall St. Rank hold BXRX as of Q1 2022.

Armistice Capital reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Armistice Capital sold 3,335 Baudax Bio, Inc. Common Stock shares in Q1 2022, an estimated $1.02M.
Armistice Capital first reported a position in Baudax Bio, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
Armistice Capital's Baudax Bio, Inc. Common Stock position peaked at $3.54M in Q4 2020.
19 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2022.

Based on Armistice Capital's 13F filing for Q1 2022, filed 16 May 2022.